FDA Approves Vumerity for Treatment for RRMS

The FDA has recently approved Vumerity for the treatment of various forms of relapsing-remitting multiple sclerosis. Vumerity works very similarly to Tecfidera, which is another Biogen MS drug. The main difference between these drugs is that Vumerity has been shown to have fewer gastrointestinal side effects than Tecfidera, which usually happens when patients first start the medication. If gastrointestinal side effects have been a problem for you with Tecfidera, Vumerity may be a better solution and you should bring it up with your MS doctor at your next office visit.

News Date : 
Saturday, November 2, 2019 (All day)


Because you deserve only the best in MS healthcare. Experience the difference.

Newsletter Sign Up

Join our mailing list today!  Receive the latest information and updates happening in MS research, treatment and care including, Healing MS, the IMSMP newsletter.

* We don’t share your information with anyone.